Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

QIAGEN N.V. Demonstrates Expanded Bioinformatics Workflows At American Society of Human Genetics; Strong Market Adoption As Researchers Analyze Genomic Data On More Than A Quarter-Million Samples In Secure Private Cloud

October 20, 2014 – 5:00 am | Edit Post

SAN DIEGO and HILDEN, Germany, October 17, 2014 /PRNewswire/ — Translational research in cancer and other diseases will benefit from new capabilities being presented at the American Society of Human Genetics annual meeting Volume of 250,000-plus DNA samples linked to Ingenuity Knowledge Base greatly exceeds any comparable database – providing superior depth for genomic…

Amicus Therapeutics, Inc. Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011

October 20, 2014 – 5:00 am | Edit Post

Across All Subgroups, Patients Treated with Migalastat Compare Favorably to Natural History on Kidney Function (eGFR) Additional GL-3 Data Further Validate Assay for Identifying Patients with Amenable Mutations

Affymetrix (Santa Clara, California) Exclusively Licenses Technology From For HLA Typing From Genotyping Data

October 20, 2014 – 5:00 am | Edit Post

SANTA CLARA, Calif.–(BUSINESS WIRE)–Affymetrix (NASDAQ:AFFX) announced today that it has exclusively licensed technology from Peptide Groove LLP that enables HLA typing of human samples from genotyping data generated from a variety of assays including the company’s Axiom genotyping assays. The partners at Peptide Groove LLP developed HLA*IMP, the first HLA typing statistical imputation method which…

Neothetics Files To Raise $63 Million To Fight Fat With An Asthma Drug

October 20, 2014 – 5:00 am | Edit Post

Neothetics, a biotech targeting fat reduction with an injectable formulation of an approved asthma drug, filed on Friday with the SEC to raise up to $63 million in an initial public offering.BusinessThe company has completed Phase 2 trials for LIPO-202, its lead candidate that is intended to reduce “subcutaneous fat in the central abdomen that is often characterized by people…

CytRx Corporation Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed

October 20, 2014 – 5:00 am | Edit Post

LOS ANGELES, Oct. 20, 2014 /PRNewswire/ –CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that a paper, titled “A Phase 1b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma,” has been published online in Cancer, the prestigious…

Apricus Biosciences Expands Development Pipeline With The In-Licensing Of U.S. Rights For Fispemifene, A Phase 2b Ready Asset, From Targeting Urological Conditions In Men

October 20, 2014 – 5:00 am | Edit Post

– Apricus Funds Upfront License Fee and 2015 Phase 2b Development Cost with $10 Million Venture Debt Financing — –Conference Call Today, Monday, Oct. 20, at 8:00 a.m. ET– SAN DIEGO, Oct. 20, 2014 (GLOBE NEWSWIRE…

ResMed Inc. Launches Data Exchange

October 20, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ –ResMed (NYSE:RMD) today announced the availability of the ResMed Data Exchange program, a comprehensive suite of software and service solutions for home medical equipment (HME) and other health care providers. ResMed Data Exchange offers timely, secure access to…

VG Life Sciences, Inc. Release: New Data Implicate Components Of Adaptive Immunity In Traumatic Brain Injury

October 20, 2014 – 5:00 am | Edit Post

SANTA BARBARA, Calif., Oct. 20, 2014 (GLOBE NEWSWIRE) — VG Life Sciences Inc., (OTCQB:VGLS) a biotechnology company, announces today that one of its scientific advisors, Dr. Richard Tobin, PhD, published data demonstrating that when there is traumatic brain injury (TBI), the body inflicts additional…

Genervon Announces ALS And PD Phase 2a Trial Results

October 20, 2014 – 5:00 am | Edit Post

PASADENA, Calif.–(BUSINESS WIRE)–Genervon Biopharmaceuticals LLC (Genervon) today announced that it has completed the analysis of its Phase 2a double blinded, randomized, placebo controlled clinical trials of Amyotrophic Lateral Sclerosis (ALS)(NCT01854294) and Parkinsons disease (PD)(NCT 01850381) for its drug candidate GM6 (also known as GM604 in the ALS trial and GM608 in the PD trial…

Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs

October 20, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ — Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the European Patent Office that the company has been granted another key patent supporting its iSONEP™ and ASONEP™ programs.

This newly issued patent, European patent No. 2087002, claims compositions of matter related to sonepcizumab, the drug substance in Lpath’s two lead compounds, iSONEP and ASONEP. Sonepcizumab is an antibody that binds to and inhibits sphingosine-1-phosphate (S1P), a bioactive lipid that has been validated as a target in multiple disease states.

Specifically, this patent claims antibody compositions and nucleic acids encoding heavy and light chains of antibodies and antibody fragments to S1P, as well as engineered plasmids and host cells designed to express a humanized monoclonal antibody to S1P. Utility claims are also granted for using anti-S1P antibodies to treat neovascularization, angiogenesis, endothelial-cell proliferation, and fibrogenesis.

iSONEP (formulated for ocular administration) and ASONEP (formulated for systemic administration) are different formulations of a first-in-class therapeutic antibody developed by Lpath’s ImmuneY2™ drug-discovery engine. Antibodies developed via this discovery engine are designed to bind and neutralize bioactive signaling lipids, such as S1P, that are involved in the proliferation and spread of cancer, age-related macular degeneration (AMD),  inflammatory and auto-immune disorders, and many other diseases.

“This patent provides key coverage in Europe for use of our anti-S1P antibodies and complements our other recently issued patents in the U.S. as well as patent claims we have been granted in Europe for wet AMD, cancer, and other conditions,” said Roger Sabbadini, Lpath’s vice president, founder, and an inventor of the issued patent.

Lpath is conducting a double-blind, four-arm Phase 2 clinical trial (the “Nexus” trial), which is evaluating iSONEP’s safety and efficacy in wet-AMD patients that have not responded well to existing anti-VEGF therapies (Lucentis®, Avastin® and Eylea®). Lpath entered into an agreement with Pfizer in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP.

Additionally, Lpath is conducting a Phase 2a trial in renal cell carcinoma patients with ASONEP; results thus far have been encouraging and suggest that additional efficacy studies—in renal cell carcinoma and/or other tumor types—are warranted.

About Lpath San Diego-based Lpath, Inc. (NASDAQ: LPTN), an antibody-platform company, is the category leader in lipid-targeted therapeutics. The company’s ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed four drug candidates, two of which—iSONEP for wet AMD and ASONEP for cancer—are currently being investigated in Phase 2 trials. The other candidates are an anti-LPA antibody, Lpathomab, a soon-to-be Phase 1 compound for neuropathic pain and neurotrauma and an anti-leukotriene antibody, Altepan, which is being studied in models of respiratory disease and inflammation. For more information, visit www.Lpath.com.

About Forward-Looking StatementsThe Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the protection against competition afforded by issued patents; the eventual commercial viability of the Company’s drug programs; and the Company’s ability to complete additional discovery and development activities for drug candidates utilizing its proprietary ImmuneY2 drug-discovery process. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business, including, without limitation: the results of the Company’s preclinical studies and clinical trials may not support further clinical development and/or the commercialization of its drug candidates; the Company may not successfully complete additional clinical trials for its product candidates on a timely basis, or at all; the Company may fail to obtain required governmental approvals for any of its drug candidates; the Company may not be successful in maintaining its commercial relationship with Pfizer Inc. or any third party that acquires Pfizer’s exclusive option to iSONEP; and the Company may not be able to secure the funds necessary to support its preclinical-development and clinical-development plans. More detailed information about the risk factors and uncertainties that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and its other filings with the SEC. Such documents may be read free of charge on the SEC’s website at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
SOURCE Lpath, Inc.